Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.

[1]  A. Nesterova,et al.  Abstract 5581: Enfortumab vedotin, an anti-Nectin-4 ADC demonstrates bystander cell killing and immunogenic cell death anti-tumor activity mechanisms of action in urothelial cancers , 2020 .

[2]  T. Powles,et al.  Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  David C. Smith,et al.  EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Lim,et al.  Gemcitabine plus carboplatin versus gemcitabine plus oxaliplatin in cisplatin-unfit patients with advanced urothelial carcinoma: a randomised phase II study (COACH, KCSG GU10-16). , 2020, European journal of cancer.

[5]  C. Nilsson,et al.  Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM). , 2020, European journal of cancer.

[6]  R. Perini,et al.  Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible , 2019, American Journal of Clinical Oncology.

[7]  M. Galsky,et al.  Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Babjuk,et al.  European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2017 Update. , 2015, European urology.

[9]  T. Powles,et al.  First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[10]  R. Bourgon,et al.  Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial , 2017, The Lancet.

[11]  D. Stover,et al.  Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models. , 2016, Cancer research.

[12]  R. Sylvester,et al.  Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Sonpavde,et al.  Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Cockcroft Dw,et al.  Prediction of Creatinine Clearance from Serum Creatinine , 1976 .

[15]  E. S. Pearson,et al.  THE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL , 1934 .